Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Under-the-Skin MS drug: can a shot replace an IV drip?

NCT ID NCT07827586

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are observing how satisfied people with relapsing-remitting multiple sclerosis are when they receive ocrelizumab as an injection under the skin instead of an intravenous infusion. The study follows about 1,800 participants across multiple countries for 12 months, including those new to treatment and those switching from IV ocrelizumab or other therapies. Participants complete questionnaires about convenience and satisfaction, and researchers track markers like relapse rates and nerve damage. The goal is to understand the real-world experience of this alternative delivery method.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ocrelizumab, a multiple sclerosis drug given as an injection under the skin
What this could lead to
If people report high satisfaction with the under-the-skin injection, it could support broader use of this easier-to-administer form of ocrelizumab for relapsing-remitting MS.
What could go wrong
This is an observational study, so it cannot prove the injection works better than other options. Satisfaction is subjective, and results may not apply to everyone with MS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of participants diagnosed with RRMS who are treated with ocrelizumab s.c. for the first time (initial treatment or treatment switch) as part of their multiple sclerosis (MS) therapy during routine clinical practice

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions). * Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information. * The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation. * Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable. Exclusion Criteria: * Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment. * Prior treatment with rituximab. * Contraindications to ocrelizumab as per the local prescribing information. * Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes. * Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results. * For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsing-remitting multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsing-remitting multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.